2. Search Result
Search Result
Results for "

IRS

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

3

Peptides

4

Natural
Products

2

Recombinant Proteins

2

Antibodies

5

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-115461
    MID-1

    		Insulin Receptor Metabolic Disease
    MID-1 is a disruptor of MG53-IRS-1 (Mitsugumin 53-insulin receptor substrate-1) interaction. MID-1 disrupts molecular association of MG53 with IRS-1 and abolishes MG53-induced IRS-1 ubiquitination and degradation in skeletal muscle, leading to elevated IRS-1 expression level and increased insulin signaling and glucose uptake .
    MID-1
  • HY-145935
    NT219

    		Insulin Receptor STAT Cancer
    NT219 is a potent and dual inhibitor of insulin receptor substrates 1/2 (IRS1/2) and STAT3. IRS1/2 and STAT3 are major signaling junctions regulated by various oncogenes. NT219 affects IRS1/2 degradation and inhibits STAT3 phosphorylation. NT219 has the potential for the research of cancer diseases .
    NT219
  • HY-100037
    NT157
    1 Publications Verification

    Tyrphostin NT157

    		 Insulin Receptor STAT Endocrinology Cancer
    NT157 (Tyrphostin NT157) is a selective IRS-1/2 inhibitor that induces Ser-phosphorylation and consequently the degradation of IRS-1/2. NT157 (Tyrphostin NT157) is a first-in-class anti-cancer agent that also targets Stat3 signaling pathway .
    NT157
  • HY-P5433F
    IRS-1 Peptide, FAM labeled

    		Insulin Receptor Others
    IRS-1 Peptide, FAM labeled is a biological active peptide. (Insulin receptor substrate)
    IRS-1 Peptide, FAM labeled
  • HY-RS06919
    IRS4 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    IRS4 Human Pre-designed siRNA Set A contains three designed siRNAs for IRS4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IRS4 Human Pre-designed siRNA Set A
    IRS4 Human Pre-designed siRNA Set A
  • HY-RS06917
    IRS1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    IRS1 Human Pre-designed siRNA Set A contains three designed siRNAs for IRS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IRS1 Human Pre-designed siRNA Set A
    IRS1 Human Pre-designed siRNA Set A
  • HY-RS06918
    IRS2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    IRS2 Human Pre-designed siRNA Set A contains three designed siRNAs for IRS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IRS2 Human Pre-designed siRNA Set A
    IRS2 Human Pre-designed siRNA Set A
  • HY-170994
    I2-IRs ligand-1

    		Imidazoline Receptor Neurological Disease Inflammation/Immunology
    I2-IRs ligand-1 (Compound 12d) is an orally active and BBB-penatrable compound. I2-IRs ligand-1 has a high affinity for imidazoline I2 receptors (I2-IRs) (pKi: 9.98). I2-IRs ligand-1 can improve cognitive impairment in senescent mice and exhibits analgesic, anti-inflammatory, and neuroprotective activities. I2-IRs ligand-1 can be used for the research of Alzheimer's disease and related pain disorders .
    I2-IRs ligand-1
  • HY-153479A
    Aganirsen sodium

    		Insulin Receptor Inflammation/Immunology
    Aganirsen sodium is a 25 mer DNA antisense oligonucleotide, which silences expression of insulin receptor substrate-1 (IRS-1).
    Aganirsen sodium
  • HY-153479
    Aganirsen

    		Insulin Receptor Inflammation/Immunology
    Aganirsen is a 25 mer DNA antisense oligonucleotide, which silences expression of insulin receptor substrate-1 (IRS-1).
    Aganirsen
  • HY-N7676
    Marein
    2 Publications Verification

    		 AMPK HDAC Cardiovascular Disease Neurological Disease Metabolic Disease
    Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a HDAC inhibitor with an IC50 of 100 μM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects .
    Marein
  • HY-N0479
    Licarin B
    1 Publications Verification

    (-)-Licarin B

    		 PPAR GLUT Metabolic Disease
    Licarin B, a nitric oxide production inhibitor extracted from the component of the seeds of Myristica fragrans, improves insulin sensitivity via PPARγ and activation of GLUT4 in the IRS-1/PI3K/AKT pathway .
    Licarin B
  • HY-107758
    Y-29794 oxalate

    		Prolyl Endopeptidase (PREP) Cancer
    Y-29794 oxalate is a selective, orally active and blood-brain barrier permeable non-peptide prolyl endopeptidase inhibitor. Y-29794 oxalate blocks the IRS1-AKT-mTORC1 pathway and inhibits tumor growth. Y-29794 oxalate is also effective in inhibiting the progression of Aβ-like deposition in the hippocampus of aging-accelerated mice (SAM) .
    Y-29794 oxalate
  • HY-15113
    Y-29794

    		Prolyl Endopeptidase (PREP) Neurological Disease Cancer
    Y-29794 is a selective, orally active inhibitor for non-peptide prolyl endopeptidase (PREP), with an IC50 of 3 nM and a Ki of 0.95 nM. Y-29794 enhances the effect of thyrotropin-releasing hormone (TRH) on the release of ACh in the rat hippocampus, exhibits potential neuroprotective efficacy. Y-29794 exhibits anticancer activity through inhibition of the IRS1-AKT-mTORC1 pathway. Y-29794 penetrates the brain-blood barrier (BBB) .
    Y-29794
  • HY-15113A
    Y-29794 tosylate

    		Prolyl Endopeptidase (PREP) Neurological Disease Cancer
    Y-29794 tosylate is a selective, orally active inhibitor for non-peptide prolyl endopeptidase (PREP), with an IC50 of 3 nM and a Ki of 0.95 nM. Y-29794 tosylate enhances the effect of thyrotropin-releasing hormone (TRH) on the release of ACh in the rat hippocampus, exhibits potential neuroprotective efficacy. Y-29794 tosylate exhibits anticancer activity through inhibition of the IRS1-AKT-mTORC1 pathway. Y-29794 tosylate penetrates the brain-blood barrier (BBB) .
    Y-29794 tosylate
  • HY-N3628
    Coronarin A

    		mTOR Ribosomal S6 Kinase (RSK) Metabolic Disease Inflammation/Immunology
    Coronarin A is an orally active natural compound that inhibits mTORC1 and S6K1 to increase IRS1 activity. Coronarin A shows anti-inflammatory activity and can also be used for type 2 diabetes mellitus research .
    Coronarin A
  • HY-N3542
    Carpachromene

    		Glycosidase Cancer
    Carpachromene is a potent α-glucosidase enzyme inhibitor. Carpachromene ameliorates insulin resistance in HepG2 cells via modulating IR/IRS1/PI3k/Akt/GSK3/FoxO1 pathway .
    Carpachromene
  • HY-P0119
    Lixisenatide
    2 Publications Verification

    		 GCGR MEK Akt MMP JNK Neurological Disease Metabolic Disease Inflammation/Immunology
    Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe −/− Irs 2+/− mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .
    Lixisenatide
  • HY-14561A
    Idazoxan hydrochloride

    RX 781094 hydrochloride

    		 Adrenergic Receptor Imidazoline Receptor Neurological Disease Endocrinology
    Idazoxan hydrochloride (RX 781094 hydrochloride) is an α2-adrenoceptor antagonist and is also a imidazoline receptors (IRs) antagonist competitively antagonized the centrally induced hypotensive effect of imidazoline-like agents (IMs). Idazoxan hydrochloride also improves motor symptoms in Parkinson’s disease, L-DOPA-induced dyskinesias, and experimental Parkinsonism .
    Idazoxan hydrochloride
  • HY-161321
    PTP1B-IN-24

    		Phosphatase Insulin Receptor Akt Metabolic Disease
    PTP1B-IN-24 (Compound 9) is a reversible PTP1B inhibitor with an IC50 value of 1.4 μM, and PTP1B-IN-24 can enhance the thermal stability of PTP1B. PTP1B-IN-24 can restore PA- (HY-N0830) induced insulin resistance by increasing the phosphorylation levels of IRS1 and AKT .
    PTP1B-IN-24
  • HY-162499
    MY17

    		Phosphatase Metabolic Disease
    MY17 is an inhibitor of protein tyrosine phosphatase 1B (PTP1B) (IC50=0.41±0.05 μM). MY17 alleviates palmitic acid (PA) -induced insulin resistance by up-regulating the expression of phosphorylated insulin receptor substrate (IRS1) and protein kinase B (AKT). By binding with PTP1B, MY17 can inhibit the activity of PTP1B, thereby improving insulin signaling and having anti-diabetic activity. MY17 can be used in the study of type 2 diabetes .
    MY17

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: